Hyogo Cancer Center ( Site 2118)

Akashi, Hyōgo 673-8558

1 studies enrolling now · 1 studies all time

What they study most

Cervical Cancer

Studies at this site

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) — Recruiting now